Gonadotrophin receptor hormone analogues in combination with add-back therapy: An update

Menopause International

Volumn 18, Issue 2, 2012, Pages 68-72

  Mclaren, James Samuel ^a   Rymer, Janice ^a   Morris, Edward ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b University Hospital   (United Kingdom)

Author keywords

Add back; GnRHa; gonadotrophins; HRT

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; GONADOTROPIN RECEPTOR; PARATHYROID HORMONE; RALOXIFENE; TIBOLONE; VITAMIN D;

DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; HUMAN; METRORRHAGIA; PREMENSTRUAL SYNDROME; REVIEW; UTERUS MYOMA;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; ENDOMETRIOSIS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; LEIOMYOMA; LIPIDS; MENSTRUATION DISTURBANCES; NORPREGNENES; PARATHYROID HORMONE; PREMENSTRUAL SYNDROME; RALOXIFENE; UTERINE DISEASES; VITAMIN D;

EID: 84861535930     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2012.012008     Document Type: Review

References (35)

1. Kiesal LA. Clinical use of GnRH analogues. Clin Endocrinol 2002; 56: 677–87
2. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99: 709–19
3. Surrey ES. Steroidal and nonsteroidal ‘add-back therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynaecologic patient. Fertil Steril 1995; 64: 673–85
4. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89: 157–61
5. Mathews KA, Meilan E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and the risk factors for coronary heart disease. N Engl J Med 1989; 321: 641–646
6. Stevenson JC, Crook D, Godsland IF. Effects of age and menopause on lipid metabolism in healthy women. Atherosclerosis 1993; 98: 83–90
7. Al-Omari WR, Nassir UN, Sulaiman WR, Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist. Int J Gynecol Obstet 1999; 66: 191–192
8. Yin SF, Lau TK, Sahota DS, Chung TKH, Chang AMZ, Haines CJ. Prospective randomized study of the effect of ‘Add-Back’ hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. Am Heart Assoc 1998; 98: 1631–5
9. Barbieri RL. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy. Am J Obstet Gynecol 1990; 162: 593–595
10. O’Brien PMS Helping women with premenstrual syndrome. BMJ 1993; 307: 1471–5
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC: American Psychiatric Association, 1994: 714–718
12. Schmidt P, Nieman L, Danaceau M, Adams L, Rubinow D. Differential behavioural effects of gonadal steroids in women with premenstrual syndrome and in control subjects. N Engl J Med 1998; 338: 209–16
13. Wyatt K, Dimmock PW, Ismail KMK, Jones PW, O’Brien S. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004; 111: 585–93
14. Segebladh B, Borgstrom A, Nyberg S, Bixo M, Sunstrom-Poromaa I, Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 2009; 201: e1–e8
15. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR, Differential behavioural effects of gonadol steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338: 209–16
16. Batzer FR. GnRH analogs:options for endometriosis-associated pain treatment. J Minim Invasive Gynecol 2006; 13: 539–45
17. Zupi E, Marconi D, Sbracia M,, et al. Add-back in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82: 1303–08
18. Surrey ES, Hornstein MD, Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99: 709–19
19. Moghissi KS, Schlaff WD, Olive DL, Skinner MA, Yin H., Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis: Long-term follow-up. Fertil Steril 1993; 59: 511–515
20. Farmer JE, Prentice A, Breeze A, Ahmad G, Duffy JMN, Watson A, Pick A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; (4):CD001297
21. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001; (4):CD000068
22. Guzick DS, Huang L, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95: 1568–73
23. Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi-Koiou V,, et al. Prolonged use of gonadotopin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas 2004; 125–32
24. Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997; 65: 102–14
25. Sowter MC, Singla AA, Lethaby A. Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding. Gynaecological Endocrinology, 2, CD001124
26. Franke HR, Froujke Snaaijer F, Houben PWH, Van der Mooren MJ. Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment – a randomized, placebo-controlled, double-blind trial. Gynaecological Endocrinology 2006; 22: 692–697
27. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100–107
28. Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981; 36: 433–45
29. Andersen J. Factors in fibroid growth. Baillieres Clin Obstet Gynaecol 1998; 12: 225–43
30. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothese. Environ Health Perspect 2000; 108: 791–793
31. Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma, a pilot study. Am J Obstet Gynecol 1985; 152: 1034–8
32. Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Clin Obstet Gynecol 2008; 22: 307–31
33. Smart OC, Hindley JT, Regan L, Gedroyc WG, Gonadotrophin-releasing hormone and magnetic-resonance guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol 2006; 108: 49–54
34. Morris EP, Rymer J, Robinson J, Fogelman I, Efficacy of tibolone as ‘add-back therapy’ in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril 2008; 89: 421–428
35. Palomba S, Russo T, Orio FJ,, et al, Effectiveness of combined GnRA analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled trial. Hum Reprod 2002; 17: 3213–9